News, views and contacts from the global Pharmaceutical industry
 

News Archive

Archive of industry news from the global pharmaceutical industry

News By Date

October 2014

Top

Ipsen to market telotristat etiprate outside North America and Japan
24 October 2014 France-based Ipsen have entered an exclusive licensing agreement with US-based Lexicon Pharmaceuticals to market telotristat etiprate outside of North America and...

Roche to invest $3bn to develop Basel site in Switzerland
24 October 2014 Roche is set to invest more than CHF3bn ($3.14bn) to develop a new research and development centre, upgrade infrastructure and renovate the existing office building at its Basel site in...

FDA accepts Eisai’s sNDA to review antiepileptic drug Fycompa
23 October 2014 Japan-based Eisai has obtained approval for review from US Food and Drug Administration (FDA) for its antiepileptic drug Fycompa...

Johnson & Johnson invests $200m to accelerate Ebola vaccine programme
23 October 2014 US-based Johnson & Johnson (J&J) have announced an investment of more than $200m, in a bid to speed up the Ebola vaccine programme at its Janssen Pharmaceutical...

FDA accepts Merck and Sanofi’s BLA to review paediatric hexavalent vaccine
22 October 2014 Merck and Sanofi Pasteur have received approval for review from US Food and Drug Administration (FDA) for investigational paediatric hexavalent vaccine,...

Baxter introduces subcutaneous immunoglobulin treatment Hyqvia in US
22 October 2014 Baxter International and Halozyme Therapeutics have announced the launch of Hyqvia in the US, a subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency...

Amgen sues Sanofi and Regeneron over patent infringement in US
21 October 2014 US-based Amgen has filed a case against Sanofi and Aventisub, formerly doing business as Aventis Pharmaceuticals and Regeneron Pharmaceuticals, in the US District Court of Delaware, over...

Apricus obtains US rights of urological treatment fispemifene from Forendo
21 October 2014 Apricus Biosciences has secured US development and commercialisation rights for a selective estrogen receptor modulator (SERM), fispemifene, from Finland-based Forendo...

Pharmacyclics’ Imbruvica receives European approval for two blood cancers
20 October 2014 US-based Pharmacyclics has received marketing approval from the European Commission (EC) for its Imbruvica (ibrutinib) to treat adult patients with relapsed or refractory mantle cell lymphoma...

Sanofi Pasteur and Immune Design to develop vaccine for herpes simplex virus
20 October 2014 Vaccines division Sanofi Pasteur has partnered with clinical-stage immunotherapy company Immune Design to develop herpes simplex virus (HSV) immune therapy....

AstraZeneca and University of Cambridge partner for research on neurodegenerative diseases
17 October 2014 AstraZeneca and subsidiary MedImmune have entered into four new collaborations with the University of Cambridge, expanding on their existing partnership....

Ranbaxy to pay $40m to settle overcharging Texas Medicaid programme litigation
17 October 2014 India-based drug maker Ranbaxy Laboratories has agreed to pay $39.75m to settle litigation about its participation in Texas Medicaid, a US health care programme for people with low incomes....

ViiV Healthcare’s HIV drug Triumeq obtains Canadian approval
16 October 2014 ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has obtained approval in Canada, for its Triumeq (dolutegravir) 50mg, abacavir 600mg, and lamivudine 300mg) to...

Genentech's IPF-treating drug Esbriet receives FDA approval
16 October 2014 Roche Group subsidiary Genentech has received approval from US Food and Drug Administration (FDA) for Esbriet (pirfenidone) drug to treat patients with idiopathic pulmonary fibrosis...

WHO warns of 10,000 new weekly Ebola cases
15 October 2014 The World Health Organisation (WHO) has warned West Africa may face up to 10,000 new Ebola cases per week within two months, due to the increasing number of...

Helsinn’s Akynzeo obtains FDA approval to treat chemotherapy-induced nausea and vomiting
15 October 2014 Switzerland-based Helsinn Healthcare has obtained US Food and Drug Administration approval for its fixed combination capsule Akynzeo to treat patients with chemotherapy-induced nausea and...

Hikma to market Eisai’s epilepsy treatment Fycompa in Middle East
14 October 2014 UK-based Hikma Pharmaceuticals has partnered with Eisai to distribute first-class epilepsy treatment Fycompa (perampanel) in the Middle East....

Gilead’s Harvoni receives FDA approval for hepatitis C genotype 1 infection
14 October 2014 Gilead Sciences has received approval from US Food and Drug Administration for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), a once-daily single tablet regimen to treat chronic hepatitis C genotype...

NPPA fines Novartis India for over pricing painkiller Voveran
13 October 2014 India's National Pharmaceutical Pricing Authority (NPPA) has reportedly fined Swiss drug maker Novartis' subsidiary in the country for Rs3bn ($48.9m), for over pricing its painkiller medicine...

Takeda UK’s Adcetris receives SMC approval to treat relapsed or refractory CD30+ HL
13 October 2014 Takeda UK has received approval from the Scottish Medicines Consortium (SMC) for its Adcetris (brentuximab vedotin) for restricted use within NHS Scotland, in order to treat adult patients...

Cipla Medpro to market Teva’s pharmaceutical products in South Africa
10 October 2014 Cipla Medpro subsidiary Medpro Pharmaceutica has entered into an agreement with Teva...


cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1243308781_ap1243308781_1857678299_874850511